Gosh, no. It's not a cap. It just means that if you're making $12 million or less on a particular drug, you're not subject to the new and more onerous, let's say, price ceiling. It's a mechanism to provide insulation from the application of the new regime. The new regime is not going to apply in that manner anyway for at least a couple of years, because of this Federal Court decision that I mentioned.
To answer your question specifically on Trikafta, no, we haven't looked at it in a formal way yet. We've had a number of discussions with the company. We've had open channels of communications with Cystic Fibrosis Canada throughout the past year, but until Trikafta is sold at non-zero prices in Canada—it's currently supplied under the special access program for free—or receives its notice of compliance from Health Canada, we won't look at it formally. That's how our regime functions.